Evaluation of Non Alcoholic Metabolic Liver Diseases in Patients Harboring Central Adiposity and Insulin Resistance by Biochemical and Functional Genomic Approaches
N/A
18 Years
60 Years
18 Years
60 Years
Open (Enrolling)
Both
Liver Disease
Both
Liver Disease
Trial Information
Evaluation of Non Alcoholic Metabolic Liver Diseases in Patients Harboring Central Adiposity and Insulin Resistance by Biochemical and Functional Genomic Approaches
Inclusion Criteria:
- Group T(n=30): patient without central adiposity, without insulin resistance,
operated for cholecystectomy or a benign liver tumor
- Group A (n=30): patient with central adiposity, insulin resistance and hepatic
steatosis (histology).
- Group B (n=30): patient with central adiposity, insulin resistance and
steatohepatitis ± hepatic fibrosis (histology).
Exclusion Criteria:
- viral or autoimmune hepatitis
- hematochromatosis
- alcohol consumption (> 20 g/24h women, >30 g/24h men)
- type 1 diabetes
- inflammation or infection before procedure
- abnormal hemostasis or coagulation- pregnancy
Type of Study:
Observational
Study Design:
Observational Model: Case Control, Time Perspective: Prospective
Principal Investigator
Michel DOFFOEL, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Hôpitaux Universitaires de Strasbourg
Authority:
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study ID:
3966
NCT ID:
NCT00844779
Start Date:
February 2009
Completion Date:
January 2011
Related Keywords:
- Liver Disease
- Metabolic syndrome- hepatic steatosis- steatohepatitis - gene expression
- Non alcoholic fatty liver disease (NFALD)
- Fatty Liver
- Liver Diseases
Name | Location |
|---|
